← Back to Search

Participants with solid tumors and hematological malignancies for Tumors

Phase 2

Waitlist Available

Research Sponsored by GlaxoSmithKline

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 weeks

Awards & highlights

Study Summary

This trial is to see if people are eligible for a different trial that may involve treatment. No treatment will occur in this trial.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants With Human Leukocyte Antigen (HLA) A Genotypes Status

Trial Design

1Treatment groups

Experimental Treatment

Group I: Participants with solid tumors and hematological malignanciesExperimental Treatment1 Intervention

Participants with solid tumors and hematological malignancies will be included. No study treatment will be administered in this study.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

GlaxoSmithKlineLead Sponsor

4,753 Previous Clinical Trials

8,069,442 Total Patients Enrolled

5 Trials studying Tumors

1,919 Patients Enrolled for Tumors

GSK Clinical TrialsStudy DirectorGlaxoSmithKline

3,595 Previous Clinical Trials

6,143,914 Total Patients Enrolled

1 Trials studying Tumors

12 Patients Enrolled for Tumors

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Recent research and studies

clinicaltrials.govStudy

Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials

2021. "Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05100316.

~5 spots leftby Apr 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.